Cancerous HLA class I expression and regulatory T cell infiltration in gastric cancer

Cancer Immunology, Immunotherapy

Volumn 61, Issue 10, 2012, Pages 1663-1669

  Ishigami, Sumiya ^a   Arigami, Takaaki ^a   Uenosono, Yoshikazu ^a   Matsumoto, Masataka ^a   Okumura, Hiroshi ^a   Uchikado, Yasuto ^a   Kita, Yoshiaki ^a   Nishizono, Yuka ^a   Maemura, Kosei ^a   Kijima, Yuko ^a   Nakajo, Akihiro ^a   Owaki, Tetsuhiro ^a   Ueno, Shinichi ^a   Hokita, Shuichi ^a   Natsugoe, Shoji ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Antitumor activity; Gastric cancer; HLA class I; Immunosuppressant; Postoperative outcome; Regulatory T cells

Indexed keywords

HLA ANTIGEN CLASS 1; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STOMACH CANCER; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; UNIVERSITY HOSPITAL;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GASTRECTOMY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; STOMACH NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84867581781     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1225-5     Document Type: Article

References (37)

1. Wong J, Jackson P (2011) Gastric cancer surgery: an American perspective on the current options and standards. Curr Treat Options Oncol 12:72-84
2. Tanizawa Y, Terashima M (2010) Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer 13:137-148
3. Gotoda T, Iwasaki M, Kusano C, Seewald S, Oda I (2010) Endoscopic resection of early gastric cancer treated by guideline and expanded National Cancer Centre criteria. Br J Surg 97:868-871
4. Nomura S, Kaminishi M (2007) Surgical treatment of early gastric cancer. Dig Surg 24:96-100
5. Kobayashi M, Okabayashi T, Sano T, Araki K (2005) Metastatic bone cancer as a recurrence of early gastric cancer - characteristics and possible mechanisms. World J Gastroenterol 11:5587-5591
6. Bhutia SK, Mallick SK, Maiti TK (2010) Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol Int 34:553-563
7. Kirkbride KC, Blobe GC (2003) Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opin Biol Ther 3:251-261
8. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Higashi H, Iwashige H, Aridome K, Hokita S, Aikou T (2002) CD3-zetachain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 94:1437-1442
9. Betts GJ, Clarke SL, Richards HE, Godkin AJ, Gallimore AM (2006) Regulating the immune response to tumours. Adv Drug Deliv Rev 58:948-961
10. Wang RF (2006) Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol 28:17-23
11. Chang X, Zheng P, Liu Y (2006) FoxP3: a genetic link between immunodeficiency and autoimmune diseases. Autoimmun Rev 5:399-402
12. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949
13. Gao Q, Qiu SJ, Fan J et al (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586-2593
14. Griffiths RW, Elkord E, Gilham DE et al (2007) Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 56:1743-1753
15. Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3? regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423-5434
16. Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T (2008) HLA-class I expression in gastric cancer. J Surg Oncol 97:605-608
17. Menon AG, Morreau H, Tollenaar RA, Alphenaar E, Van Puijenbroek M, Putter H, Janssen-Van Rhijn CM, Van De Velde CJ, Fleuren GJ, Kuppen PJ (2002) Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab Invest 82:1725-1733
18. Speetjens FM, de Bruin EC, Morreau H, Zeestraten EC, Putter H, van Krieken JH, van Buren MM, van Velzen M, Dekker-Ensink NG, van de Velde CJ, Kuppen PJ (2008) Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother 57:601-609
19. Kaneko K, Ishigami S, Kijima Y, Funasako Y, Hirata M, Okumura H, Shinchi H, Koriyama C, Ueno S, Yoshinaka H, Natsugoe S (2011) Clinical implication of HLA class I expression in breast cancer. BMC Cancer 11:454
20. de Kruijf EM, van Nes JG, Sajet A, Tummers QR, Putter H, Osanto S, Speetjens FM, Smit VT, Liefers GJ, van de Velde CJ, Kuppen PJ (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272- 1280
21. Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma - 2nd English Edition. Gastric Cancer 1:10-24
22. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagés C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pagés F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960-1964
23. Seliger B (2012) Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol Immunother 61:249-254
24. Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F (2007) Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol 601:123-131
25. Kitamura H, Torigoe T, Honma I, Sato E, Asanuma H, Hirohashi Y, Sato N, Tsukamoto T (2006) Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer. Clin Cancer Res 12:4641-4644
26. Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H (2008) Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 99:1462-1467
27. Gasparoto TH, de Souza Malaspina TS, Benevides L, de Melo EJ Jr., Costa MR, Damante JH, Ikoma MR, Garlet GP, Cavassani KA, da Silva JS, Campanelli AP (2010) Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment. Cancer Immunol Immunother 59:819-828
28. Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY (2008) Enhanced functionality of CD4? CD25(high)FoxP3? regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 14:1032-1040
29. Hillen F, Baeten CI, van de Winkel A, Creytens D, van der Schaft DW,WinnepenninckxV,GriffioenAW(2008)Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol Immunother 57:97-106
30. van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH, Hogendoorn PC, van der Burg SH, Gelderblom H, van Hall T (2010) Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitortreated gastrointestinal stromal tumors. Int J Cancer 127:899-909
31. Polcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kubler K, Buttner R, Kuhn WC, Hernando JJ (2010) Foxp3(?) cell infiltration and granzyme B(?)/Foxp3(?) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunol Immunother 59:909-919
32. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y (2011) Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat
33. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, Pommerencke T, von Knebel DM, Folprecht G, Luber B, Feyen N, Martens UM, Beckhove P, Gnjatic S, Schirmacher P, Herpel E, Weitz J, Grabe N, Jaeger D (2011) Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 71:5670-5677
34. Coe D, Begom S, Addey C, White M, Dyson J, Chai JG (2010) Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother 59:1367-1377
35. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5:e10436
36. Ferris RL, Hunt JL, Ferrone S (2005) Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33:113-133
37. Garrido F, Cabrera T, Aptsiauri N (2010) ''Hard'' and ''soft'' lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127:249-256